These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23680209)

  • 21. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.
    Lacy MQ; Rajkumar SV
    Am J Hematol; 2010 Feb; 85(2):95-6. PubMed ID: 20095057
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
    Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
    Zamarin D; Devlin SM; Arcila ME; Landau H; Lesokhin A; Lendvai N; Chung DJ; Chimento D; Weltz J; Babu D; Giralt S; Hassoun H
    Leukemia; 2013 Dec; 27(12):2422-4. PubMed ID: 23608883
    [No Abstract]   [Full Text] [Related]  

  • 24. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report.
    Sher T; Miller KC; Lee K; Chanan-Khan A
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pomalidomide (Pomalyst) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
    [No Abstract]   [Full Text] [Related]  

  • 26. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
    Michot C; Guillot B; Dereure O
    Dermatology; 2010; 220(1):49-50. PubMed ID: 19907136
    [No Abstract]   [Full Text] [Related]  

  • 27. Lenalidomide is active for extramedullary disease in refractory multiple myeloma.
    Nakazato T; Mihara A; Ito C; Sanada Y; Aisa Y
    Ann Hematol; 2012 Mar; 91(3):473-4. PubMed ID: 21647581
    [No Abstract]   [Full Text] [Related]  

  • 28. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.
    Brioli A; Melchor L; Titley I; Vijayaraghavan G; Stephens C; Zeisig A; Pawlyn C; Cavo M; Morilla R; Davies FE; Morgan GJ
    Leuk Lymphoma; 2014 Nov; 55(11):2665-8. PubMed ID: 24660850
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of multiple myeloma with thalidomide and immunomodulatory drugs].
    Hattori Y
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():596-600. PubMed ID: 17476758
    [No Abstract]   [Full Text] [Related]  

  • 33. Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide.
    Montefusco V; Galli M; Spina F; Stefanoni P; Mussetti A; Perrone G; De Philippis C; Dalto S; Maura F; Bonini C; Rezzonico F; Pennisi M; Roncari L; Soldarini M; Dodero A; Farina L; Cocito F; Caprioli C; Corradini P
    Leuk Lymphoma; 2014 Sep; 55(9):2032-7. PubMed ID: 24730540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follicular erythematous papules with keratotic spicules: a quiz. Trichodysplasia spinulosa.
    Linke M; Géraud C; Sauer C; Marx A; Goerdt S; Peitsch WK
    Acta Derm Venereol; 2014 Jul; 94(4):492-6. PubMed ID: 24322674
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
    Kuroda J; Kobayashi T; Taniwaki M
    Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
    Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
    Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
    Modi D; Mamdani H; Vettese T
    Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
    [No Abstract]   [Full Text] [Related]  

  • 39. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
    Srinivasan S; Schiffer CA
    Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide in multiple myeloma.
    Richardson PG; Mitsiades C; Hideshima T; Anderson KC
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.